Skip to content
Laurent Pharma
  • ABOUT US
    • Leadership
    • Board of directors
    • Key advisors
  • SCIENCE
    • LAU-7b
    • Membrane lipids
    • Resolution of inflammation
  • PIPELINE
    • Overview
    • Cystic fibrosis
    • COVID-19
  • NEWS & EVENTS
  • CONTACT
  • ABOUT US
    • Leadership
    • Board of directors
    • Key advisors
  • SCIENCE
    • LAU-7b
    • Membrane lipids
    • Resolution of inflammation
  • PIPELINE
    • Overview
    • Cystic fibrosis
    • COVID-19
  • NEWS & EVENTS
  • CONTACT
  • Post published:18 July 2016

Laurent Pharmaceuticals featured in Biotech Finances

Laurent Pharmaceuticals featured in Biotech Finances.
Read the article
Share

Latest News

  • Laurent Pharmaceuticals Starts Phase 3 Study with Once-a-Day Oral COVID-19 Antiviral Treatment Candidate in Hospitalized Moderate-to-Severe Patients
  • Laurent Pharmaceuticals extends COVID-19 Phase 2 study with oral antiviral LAU-7b that has showed 100% reduction in the risk of progression onto mechanical ventilation and death
  • Laurent Pharmaceuticals Announces Topline Results from its Phase 2 RESOLUTION Clinical Trial of LAU-7b for the Treatment of COVID-19

Science

  • LAU-7b
  • Membrane lipids
  • Resolution of inflammation

Pipeline

  • Overview
  • Cystic fibrosis
  • COVID-19

CONTACT

  • Address:1010 Sherbrooke St West, Suite 2401 Montréal (Québec) H3A 2R7 Canada
  • Email:info@laurentpharma.comOpens in your application
Laurent Pharmaceuticals Inc. © 2022 All Rights Reserved.